Overview

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Olaparib